Quadruple vs Tailored Therapy in the Treatment of Helicobacter Pylori Infection
Status:
Completed
Trial end date:
2020-02-15
Target enrollment:
Participant gender:
Summary
Non-bismuth quadruple therapies have been proposed as potential strategies in improving the
efficacy of first-line treatments. The non-bismuth quadruple therapy in its concomitant
variant consists of proton pump inhibitor, amoxicillin, nitroimidazole and clarithromycin
given concurrently twice daily. As a result of concurrent administration this therapy has
given better results according to some studies in comparison to sequential variants. However,
this therapy, as well suffers from the aforementioned increase in antibiotic resistance.
Therefore, the aim of this study was to compare concomitant non-bismuth quadruple therapy
with a tailored therapy based on antibiotic strain susceptibility testing.